Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells

References

• Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005; 43:1133 - 9; http://dx.doi.org/10.1055/s-2005-858638; PMID: 16220453
   PubMed Web of Science ®Google Scholar
• Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009; 135:855 - 66; http://dx.doi.org/10.1007/s00432-009-0583-7; PMID: 19363621
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075 - 83; http://dx.doi.org/10.1200/JCO.2009.25.3641; PMID: 20085938
   PubMed Web of Science ®Google Scholar
• Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70:2146 - 57; http://dx.doi.org/10.1158/0008-5472.CAN-09-4355; PMID: 20179189
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330 - 8; http://dx.doi.org/10.1038/nrc1074; PMID: 12724731
   PubMed Web of Science ®Google Scholar
• Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407 - 12; PMID: 7882343
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587:194 - 205; PMID: 12084461
   PubMed Web of Science ®Google Scholar
• Dynlacht BD. Live or let die: E2F1 and PI3K pathways intersect to make life or death decisions. Cancer Cell 2008; 13:1 - 2; http://dx.doi.org/10.1016/j.ccr.2007.12.017; PMID: 18167332
   PubMed Web of Science ®Google Scholar
• Kasahara M, Takahashi Y, Nagata T, Asai S, Eguchi T, Ishii Y, et al. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer. Clin Cancer Res 2000; 6:2707 - 11; PMID: 10914714
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125:733 - 47; http://dx.doi.org/10.1016/j.cell.2006.03.035; PMID: 16647110
   PubMed Web of Science ®Google Scholar
• Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008; 76:19 - 27; http://dx.doi.org/10.1016/j.bcp.2008.03.025; PMID: 18508035
   PubMed Web of Science ®Google Scholar
• Ikeda M, Kurose A, Takatori E, Sugiyama T, Traganos F, Darzynkiewicz Z, et al. DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. Int J Oncol 2010; 36:1081 - 8; PMID: 20372780
   PubMed Web of Science ®Google Scholar
• Peters GJ, Laurensse E, Leyva A, Pinedo HM. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 1987; 23:1869 - 81; http://dx.doi.org/10.1016/0277-5379(87)90053-8; PMID: 3436351
   PubMedGoogle Scholar
• Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67:5840 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-06-4615; PMID: 17575152
   PubMed Web of Science ®Google Scholar
• Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 2008; 415:97 - 110; http://dx.doi.org/10.1042/BJ20080639; PMID: 18498248
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932 - 40; http://dx.doi.org/10.1038/sj.onc.1209990; PMID: 17001314
   PubMed Web of Science ®Google Scholar
• Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8:393 - 412; http://dx.doi.org/10.1016/j.coph.2008.08.004; PMID: 18721898
   PubMed Web of Science ®Google Scholar
• Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, Eramo A, et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 2009; 28:3586 - 96; http://dx.doi.org/10.1038/onc.2009.215; PMID: 19633683
   PubMed Web of Science ®Google Scholar
• Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008; 68:5915 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-08-0757; PMID: 18632646
   PubMed Web of Science ®Google Scholar
• Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B, et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008; 7:392 - 6; http://dx.doi.org/10.4161/cbt.7.3.5366; PMID: 18075305
   PubMed Web of Science ®Google Scholar
• Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010; 299:22 - 8; http://dx.doi.org/10.1016/j.canlet.2010.07.020; PMID: 20727673
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100:2402 - 10; http://dx.doi.org/10.1111/j.1349-7006.2009.01315.x; PMID: 19764996
   PubMed Web of Science ®Google Scholar
• Liu Z, Roberts TM. Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 2006; 5:675 - 7; http://dx.doi.org/10.4161/cc.5.7.2605; PMID: 16627990
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497 - 500; http://dx.doi.org/10.1126/science.1099314; PMID: 15118125
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129 - 39; http://dx.doi.org/10.1056/NEJMoa040938; PMID: 15118073
   PubMed Web of Science ®Google Scholar
• Guillard S, Clarke PA, Te Poele R, Mohri Z, Bjerke L, Valenti M, et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009; 8:443 - 53; http://dx.doi.org/10.4161/cc.8.3.7643; PMID: 19177002
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67:7960 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-07-2154; PMID: 17804702
   PubMed Web of Science ®Google Scholar
• Tan WL, Bhattacharya B, Loh M, Balasubramanian I, Akram M, Dong D, et al. Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther 2011; 11:599 - 608; http://dx.doi.org/10.4161/cbt.11.6.14670; PMID: 21378502
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar